醫藥中間體市場－全球產業規模、佔有率、趨勢、機會、預測：按產品、應用、地區和競爭對手分類，2021-2031年

全球醫藥中間體市場預計將從 2025 年的 436.4 億美元成長到 2031 年的 605.5 億美元，複合年成長率為 5.61%。

醫藥中間體是合成活性藥物成分 (API) 的關鍵結構單元，是重要的化合物。全球醫藥中間體市場的發展主要受慢性病日益普遍、治療方法不斷創新以及學名藥生產規模擴大的推動。此外，對合約研發生產機構 (CDMO) 的依賴性不斷增強也為該行業提供了支持。推動這一市場擴張的主要因素是藥物研發領域的大量資金投入。根據歐洲製藥工業協會聯合會 (EFPIA) 的報告，到 2024 年，歐洲以研發為導向的製藥業在研發方面的投資金額約為 550 億歐元。如此龐大的投資凸顯了市場對新藥研發所需複雜化學前驅物的強勁需求。

儘管成長前景強勁，但市場仍面臨與嚴格的環境法規和合法規相關的重大障礙。製造商必須遵守有關化學品安全和污染防治的嚴格國際標準，這通常需要耗資巨大的基礎設施升級和製程調整。這種複雜的法規環境，加上原物料價格的波動，造成了營運壓力，可能會限制產能並阻礙全球醫藥中間體市場的進一步擴張。

市場促進因素

全球慢性病和老齡化相關疾病發生率的上升是推動醫藥中間體產業發展的主要動力，顯著增加了治療藥物生產所需的化學前體數量。隨著癌症等複雜疾病在全球範圍內負擔加重，製造商面臨著供應合成靶向藥物活性成分（API）所需複雜中間體的巨大壓力。世界衛生組織（WHO）2024年2月發布的題為《全球癌症負擔》的新聞稿指出，2022年全球新增癌症病例預計將達到2,000萬例，凸顯了治療藥物生產需求的重要性。這一趨勢在主要市場尤為顯著，美國癌症協會發布的《2024年癌症事實與數據》預測，美國新增癌症病例數將首次超過200萬例。這些人口結構的變化正直接促使該產業擴大癌症相關中間體的產能，以便患者能夠獲得挽救生命的治療。

全球對經濟實惠的學名藥的需求不斷成長，進一步推動了市場擴張，因為這需要大規模的化學合成。隨著醫療保健系統尋求控制不斷上漲的成本，對專利到期療法的依賴性日益增強，從而帶動了學名藥大規模生產所需基礎成分的消耗。這種轉變迫使中間供應商最佳化合成路線並加強供應鏈，以滿足學名藥產業龐大的需求。根據美國可及藥品協會 (Accessible Medicines Association) 於 2024 年 9 月發布的《2024 年美國非專利和生物類似藥節省報告》，學名藥和生物類似藥占美國所有處方箋的 90%。如此高的市場滲透率要求化學品製造商實施高效的大規模生產流程，以滿足學名藥行業對原料的巨大需求。

市場挑戰

嚴格的環境法規和合法規對全球醫藥中間體市場的擴張構成重大阻礙。各國政府強制執行有關化學品安全、廢棄物管理和污染防治的嚴格通訊協定，迫使製造商將大量資金投入無法產生收益的基礎建設。這些合規要求推高了營運成本，延長了生產週期，並直接降低了企業應對全球需求波動所需的靈活性。因此，企業往往面臨利潤率下降，難以再投資於設施現代化和產能擴張。

這些監管壓力對工業產出和競爭力產生了重大影響。據歐洲化學工業理事會（Cefic）稱，作為醫藥中間體主要來源的整個歐洲化學行業的運轉率在2024年將停滯在75%左右，遠低於歷史平均水平，這主要是由於高昂的監管成本和運營成本的雙重負擔。如此低的運轉率利用率凸顯了合規義務如何限制生產效率。最終，這些營運限制會造成供應瓶頸，並透過推高關鍵醫藥前驅物的成本結構來阻礙整體市場成長潛力。

市場趨勢

隨著製藥公司將韌性置於低成本採購之上，以美國、歐洲和「中國+1」策略為驅動的供應鏈多元化策略轉型正在從根本上改變市場結構。面對地緣政治風險和供應脆弱性，主要企業投入大量資金加強國內生產基地，以減少對單一海外供應來源的依賴。為了支持這種透過區域多元化實現安全保障的趨勢，DCAT價值鏈洞察在其2025年11月發布的「產業熱點新聞」更新報告中指出，再生元製藥計畫投資20億美元用於其在美國的製藥生產業務，以增強國內產能。

同時，胜肽、寡核苷酸和抗體藥物複合體(ADC) 等特種中間體的擴張正在推動產業內的技術進步。與傳統的小分子藥物不同，這些複雜的藥物需要高度精密的合成工藝，例如固相肽合成，並正在形成其自身的高價值市場細分領域。隨著對 GLP-1促效劑和標靶癌症療法的需求激增，合約研發生產機構 (CDMO) 不得不積極擴大其專業生產能力，以應對這些複雜的化學過程。例如，DCAT Value Chain Insights 在 2025 年 4 月報道稱，Corden Pharma 已決定進行超過 10 億歐元的戰略投資，以提高其胜肽的生產能力。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球醫藥中間體市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依產品類型（化學中間體、醫藥原料中間體、客製化中間體、其他）
  • 依用途分類（鎮痛藥、抗發炎藥、循環系統藥物、抗糖尿病藥物、抗癌藥物等）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

第6章：北美醫藥中間體市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國別分析
  • 美國
  • 加拿大
  • 墨西哥

第7章：歐洲醫藥中間體市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國別分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

第8章：亞太地區醫藥中間體市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國別分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

第9章：中東和非洲醫藥中間體市場展望

• 市場規模及預測
• 市佔率及預測
• 中東與非洲：國別分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章：南美洲醫藥中間體市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國別分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進因素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 近期趨勢

第13章 全球醫藥中間體市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的議價能力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Aceto Corporation
• BASF SE
• Chiracon GmbH
• Yin-sheng Bio-tech Co. Ltd.
• Dishman Pharmaceuticals & Chemicals Ltd
• Green Vision Life Sciences Pvt Ltd
• Midas Pharma GmbH
• Sanofi SA
• Vertellus Holdings LLC.
• Lonza Group AG

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Pharmaceutical Intermediates Market is projected to expand from USD 43.64 Billion in 2025 to USD 60.55 Billion by 2031, reflecting a Compound Annual Growth Rate (CAGR) of 5.61%. Pharmaceutical intermediates are specialized chemical compounds that function as the essential building blocks for synthesizing active pharmaceutical ingredients (APIs). This global market is driven by the increasing prevalence of chronic diseases, which demands continuous therapeutic innovation, alongside the growing production of generic medicines. Additionally, the industry is supported by a rising reliance on Contract Development and Manufacturing Organizations (CDMOs). A key factor fueling this expansion is the significant capital dedicated to drug discovery; the European Federation of Pharmaceutical Industries and Associations reported that the research-based pharmaceutical sector invested roughly €55,000 million in R&D across Europe in 2024. This substantial investment highlights the strong demand for the complex chemical precursors necessary for developing new medications.

Despite these favorable growth prospects, the market faces a major hurdle regarding strict environmental and regulatory compliance. Manufacturers are required to adhere to rigorous international standards regarding chemical safety and pollution control, often mandating expensive infrastructure upgrades and process adjustments. This complicated regulatory environment, combined with the potential for raw material price volatility, creates operational pressures that may limit production capacities and hinder the broader expansion of the global pharmaceutical intermediates market.

Market Driver

The rising global incidence of chronic and age-related disorders serves as a primary driver for the pharmaceutical intermediates sector, significantly increasing the volume of chemical precursors needed for therapy production. As the burden of complex diseases like cancer grows worldwide, manufacturers face intense pressure to supply advanced intermediate chemicals required for synthesizing targeted Active Pharmaceutical Ingredients (APIs). According to the World Health Organization's 'Global Cancer Burden' press release in February 2024, there were an estimated 20 million new cancer cases globally in 2022, emphasizing the critical scale of demand for therapeutic manufacturing. This trend is particularly evident in major markets; the American Cancer Society's 'Cancer Facts & Figures 2024' projected that new cancer cases in the United States would exceed 2 million for the first time. These demographic shifts directly compel the industry to boost production capacities for oncology-related intermediates to ensure patient access to life-saving treatments.

The accelerating global demand for cost-effective generic medications further supports market expansion by requiring high-volume chemical synthesis. As healthcare systems seek to control rising costs, the reliance on off-patent therapeutics has increased, driving the consumption of the fundamental building blocks necessary for their mass production. This shift forces intermediate suppliers to optimize synthetic routes and strengthen supply chains to meet the bulk volume needs of the generics sector. According to the Association for Accessible Medicines' '2024 U.S. Generic & Biosimilar Medicines Savings Report' from September 2024, generic and biosimilar medicines comprised 90% of all prescriptions filled in the United States. This significant market penetration obliges chemical manufacturers to adopt efficient, large-scale processes to satisfy the substantial material requirements of the generic drug industry.

Market Challenge

Strict environmental and regulatory compliance constitutes a formidable obstacle to the expansion of the Global Pharmaceutical Intermediates Market. As governments enforce rigorous protocols regarding chemical safety, waste management, and pollution control, manufacturers are forced to allocate significant capital toward non-revenue-generating infrastructure upgrades. These compliance mandates raise operational costs and extend production timelines, directly reducing the agility needed to respond to fluctuating global demand. Consequently, companies often experience diminished profit margins, which limits their ability to reinvest in facility modernization or capacity expansion.

This regulatory pressure has a tangible impact on industrial output and competitiveness. According to the European Chemical Industry Council (Cefic), capacity utilization across the European chemical sector-a vital source for pharmaceutical intermediates-stagnated at approximately 75% in 2024, a figure significantly below the historical average due to the compounding burdens of high regulatory and operational costs. Such underutilization underscores how compliance obligations can restrict manufacturing throughput. Ultimately, these operational constraints impede the market's overall growth potential by causing supply bottlenecks and driving up the cost structure of essential pharmaceutical precursors.

Market Trends

The strategic pivot toward Western and "China Plus One" supply chain diversification is fundamentally reshaping the market as pharmaceutical companies value resilience over low-cost sourcing. Facing geopolitical risks and supply vulnerabilities, major industry players are actively reshoring production to the United States and Europe or diversifying into alternative Asian hubs to secure their intermediate supply chains. This structural realignment drives significant capital allocation into domestic manufacturing resilience, reducing dependence on single-source foreign entities. Validating this trend toward localized security, DCAT Value Chain Insights reported in its November 2025 'Top Industry News' update that Regeneron plans to invest $2 billion in United States drug manufacturing operations to bolster its domestic production capabilities.

Simultaneously, the expansion of specialized intermediates for peptides, oligonucleotides, and Antibody-Drug Conjugates is driving a technological evolution within the sector. Unlike traditional small molecules, these complex modalities require highly sophisticated synthetic steps, such as solid-phase peptide synthesis, creating a distinct, high-value market segment. The surging demand for GLP-1 agonists and targeted oncology therapies compels CDMOs to aggressively expand specialized capacity to handle these intricate chemical processes. Illustrating this investment in high-value infrastructure, DCAT Value Chain Insights noted in April 2025 that CordenPharma committed to a strategic investment exceeding €1 billion to increase its peptide manufacturing capacity.

Key Market Players

• Aceto Corporation
• BASF SE
• Chiracon GmbH
• Yin-sheng Bio-tech Co. Ltd.
• Dishman Pharmaceuticals & Chemicals Ltd
• Green Vision Life Sciences Pvt Ltd
• Midas Pharma GmbH
• Sanofi SA
• Vertellus Holdings LLC.
• Lonza Group AG

Report Scope

In this report, the Global Pharmaceutical Intermediates Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Pharmaceutical Intermediates Market, By Product

• Chemical Intermediates
• Bulk Drug Intermediates
• Custom Intermediates
• Others

Pharmaceutical Intermediates Market, By Application

• Analgesics
• Anti-inflammatory Drug
• Cardiovascular Drugs
• Anti-Diabetic Drugs
• Anti-Cancer Drugs
• Others

Pharmaceutical Intermediates Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Pharmaceutical Intermediates Market.

Available Customizations:

Global Pharmaceutical Intermediates Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Pharmaceutical Intermediates Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product (Chemical Intermediates, Bulk Drug Intermediates, Custom Intermediates, Others)
  • 5.2.2. By Application (Analgesics, Anti-inflammatory Drug, Cardiovascular Drugs, Anti-Diabetic Drugs, Anti-Cancer Drugs, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Pharmaceutical Intermediates Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product
  • 6.2.2. By Application
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Pharmaceutical Intermediates Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product
      • 6.3.1.2.2. By Application
  • 6.3.2. Canada Pharmaceutical Intermediates Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product
      • 6.3.2.2.2. By Application
  • 6.3.3. Mexico Pharmaceutical Intermediates Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product
      • 6.3.3.2.2. By Application

7. Europe Pharmaceutical Intermediates Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product
  • 7.2.2. By Application
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Pharmaceutical Intermediates Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product
      • 7.3.1.2.2. By Application
  • 7.3.2. France Pharmaceutical Intermediates Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product
      • 7.3.2.2.2. By Application
  • 7.3.3. United Kingdom Pharmaceutical Intermediates Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product
      • 7.3.3.2.2. By Application
  • 7.3.4. Italy Pharmaceutical Intermediates Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product
      • 7.3.4.2.2. By Application
  • 7.3.5. Spain Pharmaceutical Intermediates Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product
      • 7.3.5.2.2. By Application

8. Asia Pacific Pharmaceutical Intermediates Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product
  • 8.2.2. By Application
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Pharmaceutical Intermediates Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product
      • 8.3.1.2.2. By Application
  • 8.3.2. India Pharmaceutical Intermediates Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product
      • 8.3.2.2.2. By Application
  • 8.3.3. Japan Pharmaceutical Intermediates Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product
      • 8.3.3.2.2. By Application
  • 8.3.4. South Korea Pharmaceutical Intermediates Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Product
      • 8.3.4.2.2. By Application
  • 8.3.5. Australia Pharmaceutical Intermediates Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Product
      • 8.3.5.2.2. By Application

9. Middle East & Africa Pharmaceutical Intermediates Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product
  • 9.2.2. By Application
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Pharmaceutical Intermediates Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product
      • 9.3.1.2.2. By Application
  • 9.3.2. UAE Pharmaceutical Intermediates Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product
      • 9.3.2.2.2. By Application
  • 9.3.3. South Africa Pharmaceutical Intermediates Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product
      • 9.3.3.2.2. By Application

10. South America Pharmaceutical Intermediates Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product
  • 10.2.2. By Application
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Pharmaceutical Intermediates Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product
      • 10.3.1.2.2. By Application
  • 10.3.2. Colombia Pharmaceutical Intermediates Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product
      • 10.3.2.2.2. By Application
  • 10.3.3. Argentina Pharmaceutical Intermediates Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product
      • 10.3.3.2.2. By Application

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Pharmaceutical Intermediates Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Aceto Corporation
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. BASF SE
• 15.3. Chiracon GmbH
• 15.4. Yin-sheng Bio-tech Co. Ltd.
• 15.5. Dishman Pharmaceuticals & Chemicals Ltd
• 15.6. Green Vision Life Sciences Pvt Ltd
• 15.7. Midas Pharma GmbH
• 15.8. Sanofi SA
• 15.9. Vertellus Holdings LLC.
• 15.10. Lonza Group AG

16. Strategic Recommendations

17. About Us & Disclaimer